A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab A systematic review of the effectiveness of adalimumab
106 Health economics TABLE 56 Second TNF inhibitor following adalimumab (40,000 patients) Option Cost (£) QSE QALYs QSE Etan 58,871 184 5.7622 0.0235 Infl 46,036 146 5.0558 0.0224 Base 15,972 36 4.9302 0.0206 Comparison Diff. cost (£) QSE Diff. QALY QSE Etan – Base 42,899 179 0.8320 0.0231 Infl – Base 30,064 142 0.1256 0.0220 Etan – Infl 12,835 216 0.7064 0.0234 Comparison ICER (£ per QALY) Quasi-CI Etan – Base 51,600 48,800 to 54,600 Infl – Base 239,000 177,000 to 368,000 Etan – Infl 18,200 16,900 to 19,600 TABLE 57 Second TNF inhibitor following etanercept (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 45,666 95 4.8230 0.0138 Infl 45,424 91 4.8559 0.0139 Base 15,653 23 4.6988 0.0129 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 30,013 93 0.1242 0.0136 Infl – Base 29,773 89 0.1571 0.0137 Adal – Infl 240 122 –0.0329 0.0138 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 242,000 198,000 to 310,000 Infl – Base 190,000 161,000 to 230,000 Adal – Infl Infl more effective than Adal; diff. cost not significant TABLE 58 Second TNF inhibitor following infliximab (40,000 patients) Option Cost (£) QSE QALYs QSE Adal 46,365 152 5.1019 0.0223 Etan 58,844 185 5.7985 0.0237 Base 15,994 36 4.8872 0.0206 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 30,371 148 0.2147 0.026 Etan – Base 42,850 179 0.9113 0.0232 Etan – Adal 12,479 221 0.6966 0.0234 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 141,000 118,000 to 177,000 Etan – Base 47,000 44,700 to 49,600 Etan – Adal 17,900 16,700 to 19,400
TABLE 59 Third TNF inhibitor following adalimumab and etanercept (100,000 patients) © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 Option Cost (£) QSE QALYs QSE Infl 44,122 90 4.3990 0.0133 Base 15,134 23 4.3289 0.0123 Comparison Diff. cost (£) QSE Diff. QALY QSE Infl – Base 28,988 87 0.0701 0.0133 Comparison ICER (£ per QALY) Quasi-CI Infl – Base 414,000 300,000 to 667,000 TABLE 60 Third TNF inhibitor following adalimumab and infliximab (20,000 patients) Option Cost (£) QSE QALYs QSE Etan 56,640 256 5.2256 0.0318 Base 1,391 50 4.4743 0.0279 Comparison Diff. cost (£) QSE Diff. QALY QSE Etan – Base 41,250 248 0.7513 0.0319 Comparison ICER (£ per QALY) Quasi-CI Etan – Base 54,900 50,600 to 60,100 TABLE 61 Third TNF inhibitor following etanercept and adalimumab (100,000 patients) Option Cost (£) QSE QALYs QSE Infl 44,299 90 4.4228 0.0133 Base 15,130 23 4.3222 0.0123 Comparison Diff. cost (£) QSE Diff. QALY QSE Infl – Base 29169 88 0.1006 0.0134 Comparison ICER (£ per QALY) Quasi-CI Infl – Base 290,000 229,000 to 395,000 TABLE 62 Third TNF inhibitor following etanercept and infliximab (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 44,497 94 4.3904 0.0131 Base 15,130 23 4.3231 0.0123 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 29,367 92 0.0673 0.0132 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 437,000 313,000 to 720,000 107
- Page 72 and 73: 56 TABLE 12 Description of included
- Page 74 and 75: 58 TABLE 13 Quality of included RCT
- Page 76 and 77: 60 Effectiveness per week and escal
- Page 78 and 79: 62 Effectiveness significant advant
- Page 80 and 81: 64 Effectiveness Review: Infliximab
- Page 82 and 83: 66 Effectiveness Review: Infliximab
- Page 84 and 85: 68 Effectiveness FIGURE 44 Malignan
- Page 86 and 87: 70 TABLE 17 Effectiveness Summary o
- Page 89 and 90: Summary of review of existing econo
- Page 91 and 92: TABLE 20 Summary of published ICERs
- Page 93 and 94: TABLE 21 Published etanercept econo
- Page 95 and 96: TABLE 23 Published economic analyse
- Page 97 and 98: TABLE 25 Treatment sequences: adali
- Page 99 and 100: management of RA, i.e. 1st and 2nd
- Page 101 and 102: To estimate the long-term consequen
- Page 103 and 104: TABLE 32 TNF inhibitors as last act
- Page 105 and 106: TABLE 34 Basic structure of the mod
- Page 107 and 108: een quit on grounds of toxicity, ad
- Page 109 and 110: TABLE 39 Strategy set: adalimumab a
- Page 111 and 112: TABLE 43 Beta distributions for HAQ
- Page 113 and 114: TABLE 44 Early cessation of DMARDs:
- Page 115 and 116: TABLE 46 Unit costs for tests and v
- Page 117 and 118: following properties, according to
- Page 119 and 120: TABLE 52 Base case: TNF inhibitors
- Page 121: TABLE 54 Base case: TNF inhibitors
- Page 125 and 126: TABLE 65 Sensitivity analyses: TNF
- Page 127 and 128: TABLE 67 Sensitivity analyses: TNF
- Page 129: The substantial economic impact of
- Page 133 and 134: Summary Effectiveness: principal fi
- Page 135 and 136: inhibitors, although the incrementa
- Page 137 and 138: introduce bias which generally exag
- Page 139: Adalimumab, etanercept and inflixim
- Page 143 and 144: 1. Jobanputra P, Barton P, Bryan S,
- Page 145 and 146: 46. Young A, Dixey J, Cox N, Davies
- Page 147 and 148: tumor necrosis factor therapy in th
- Page 149 and 150: arthritis: a 12-week, double-blind,
- Page 151 and 152: 171. Geborek P, Crnkic M, Petersson
- Page 153 and 154: 216. Schotte H, Willeke P, Mickholz
- Page 155 and 156: The Health Assessment Questionnaire
- Page 157 and 158: Cochrane Library (CENTRAL) 2005 Iss
- Page 159 and 160: Appendix 3 © Queen’s Printer and
- Page 161: TABLE 69 Studies excluded from clin
- Page 164 and 165: 148 Appendix 4 TABLE 71 Meta-analys
- Page 166 and 167: 150 Appendix 4 TABLE 73 Meta-analys
- Page 168 and 169: 152 Appendix 4 Infliximab versus pl
- Page 170 and 171: 154 Appendix 4 Infliximab plus MTX
TABLE 59 Third TNF inhibitor following <strong>adalimumab</strong> and etanercept (100,000 patients)<br />
© Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
Health Technology Assessment 2006; Vol. 10: No. 42<br />
Option Cost (£) QSE QALYs QSE<br />
Infl 44,122 90 4.3990 0.0133<br />
Base 15,134 23 4.3289 0.0123<br />
Comparison Diff. cost (£) QSE Diff. QALY QSE<br />
Infl – Base 28,988 87 0.0701 0.0133<br />
Comparison ICER (£ per QALY) Quasi-CI<br />
Infl – Base 414,000 300,000 to 667,000<br />
TABLE 60 Third TNF inhibitor following <strong>adalimumab</strong> and infliximab (20,000 patients)<br />
Option Cost (£) QSE QALYs QSE<br />
Etan 56,640 256 5.2256 0.0318<br />
Base 1,391 50 4.4743 0.0279<br />
Comparison Diff. cost (£) QSE Diff. QALY QSE<br />
Etan – Base 41,250 248 0.7513 0.0319<br />
Comparison ICER (£ per QALY) Quasi-CI<br />
Etan – Base 54,900 50,600 to 60,100<br />
TABLE 61 Third TNF inhibitor following etanercept and <strong>adalimumab</strong> (100,000 patients)<br />
Option Cost (£) QSE QALYs QSE<br />
Infl 44,299 90 4.4228 0.0133<br />
Base 15,130 23 4.3222 0.0123<br />
Comparison Diff. cost (£) QSE Diff. QALY QSE<br />
Infl – Base 29169 88 0.1006 0.0134<br />
Comparison ICER (£ per QALY) Quasi-CI<br />
Infl – Base 290,000 229,000 to 395,000<br />
TABLE 62 Third TNF inhibitor following etanercept and infliximab (100,000 patients)<br />
Option Cost (£) QSE QALYs QSE<br />
Adal 44,497 94 4.3904 0.0131<br />
Base 15,130 23 4.3231 0.0123<br />
Comparison Diff. cost (£) QSE Diff. QALY QSE<br />
Adal – Base 29,367 92 0.0673 0.0132<br />
Comparison ICER (£ per QALY) Quasi-CI<br />
Adal – Base 437,000 313,000 to 720,000<br />
107
Change language